Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Cutera Launches truSculpt® iD, Personalized Body Sculpting: The Next Evolution


Posted on: 16 Jul 18

BRISBANE, Calif., July 16, 2018 (GLOBE NEWSWIRE) -- CUTERA, INC., (Nasdaq:CUTR) (“Cutera” or the “Company”) a leading provider of laser, light and other energy-based aesthetic systems for practitioners worldwide, today announces the availability of truSculpt® iD, the next evolution in body sculpting with unique hands-free capability and the ability to treat a full abdomen in as little as 15 minutes.  truSculpt iD’s sleek design and comprehensive handpiece options give physicians and other qualified practitioners the flexibility to deliver personalized body sculpting to patients through either a hand-held or hands-free treatment technique in a fraction of the time required by other body sculpting options on the market. This, alongside its unique ability to treat various fat densities and all skin types, highlights the versatility of the truSculpt iD technology.

A non-surgical body sculpting system, truSculpt iD uses innovative monopolar radio frequency (RF) technology to selectively target fat and therapeutically heat it until fat cells are slowly removed and excreted through the body naturally. Penetrating deep to treat the entire fat layer from skin to muscle, truSculpt iD is clinically proven for permanent fat cell destruction. With real-time temperature control working to provide consistent results, studies have shown an average fat reduction of 24 percent, with patients seeing improvements 6-12 weeks following the first treatment.

“truSculpt iD allows patients to achieve truly tailored results in a significantly shorter time frame, making it a very appealing non-invasive option for permanently eliminating fat cells in stubborn areas,” commented Dr. Anne Chapas, internationally acclaimed dermatologic surgeon and Medical Director of Union Square Laser Dermatology. “With such an efficient technology and the ability to treat multiple body areas simultaneously, we are able to treat more patients in a shorter period of time as a result.”

“We are proud to announce the availability of truSculpt iD, supporting our mission to develop powerful technologies that advance the medical aesthetics industry and help clinicians expand their body sculpting practice,” said James Reinstein, President and CEO of Cutera, Inc. “truSculpt iD delivers results regardless of the patient’s shape or body type - allowing physicians to effectively treat those who might not be candidates for other contouring procedures. We believe the truSculpt iD will expand the market with this comfortable, safe, and highly accelerated sculpting procedure. Additionally, truSculpt iD further enhances our expanding portfolio of devices which incorporate a disposable element.  These new consumables allow us to participate in procedure-based recurring revenue along with our physician customers.”

The launch of truSculpt iD comes at a time of significant growth for the industry. Research shows non-surgical fat reduction was the top non-surgical and non-invasive procedure in 2017, with procedures increasing by 24.7 percent. Looking ahead, the body shaping and skin tightening market is expected to expand by 14.5 percent year-over-year.

Additional Resources:

About Cutera, Inc.
Brisbane, California-based Cutera is a leading provider of laser and other energy-based aesthetic systems for practitioners worldwide. Since 1998, Cutera has been developing innovative, easy-to-use products that enable physicians and other qualified practitioners to offer safe and effective aesthetic treatments to their patients. For more information, call 1-888-4CUTERA or visit www.cutera.com

*ASAPS 2017 https://www.surgery.org/sites/default/files/ASAPS-Stats2017.pdf

Contact
Codeword on behalf of Cutera
Liv Allen
cutera@codeword.com
415-370-0716

GlobeNewswire
globenewswire.com

Last updated on: 16/07/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.